

## ANSWERING REVIEWERS



July 11, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 11429-review.doc).

**Title:** Promising new treatment targets in patients with fibrosing lung disorders

**Author:** Martina Sterclova, Martina Vasakova

**Name of Journal:** *World Journal of Clinical Cases*

**ESPS Manuscript NO:** 11429

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

- (1) 02416403 No revision suggested
- (2) 00608195 The abstract was re-written.
- (3) 00608190 Plasma membrane section was modified.
- (4) 00505786 1-The method section has not been provided, since the article had not intended to be a consistent metaanalysis of available data.
  - 2-Introduction was expanded.
  - 3-More data of THG beta were provided.
  - 4-Authors state that the role of TNF-alpha inhibitors in treatment of CTD-ILD needs to be established, further studies might find it either possible treatment modality or a blind alley.
  - 5- Recent NEJM publication on nintedanib was added.
  - 6-Recent NEJM paper on pirfenidone was included.
  - 7-reference 33 skipped.
  - 8-CTD related ILD were separated into individual section and data concerning cyclophosphamide, mycophenolate and rituximab in systemic sclerosis patients were added.
  - 9-other pathways including developmental pathways and epithelial-mesenchymal transition were included.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Clinical Cases*

Sincerely yours,

Martina Sterclova, MD, PhD.

Department of Respiratory Medicine, 1<sup>st</sup> Medical Faculty of Charles University and Thomayer Hospital

Thomayer Hospital

Videnska 800

Prague 4

140 00

Czech Republic

Phone: +420 261 082 163

Fax: +420 261 082 206

e-mail: martinasafrankova@seznam.cz